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Summary
Controlling protein dimerization with small molecules
has broad application to the study of protein function.
Rapamycinhas twobinding surfaces: one that binds to
FKBP12and theother to theFrbdomainofmTor/FRAP,
directing their dimerization. Rapamycin is a potent cell
growth inhibitor, but chemical modification of the sur-
facecontactingFrballeviates this effect. Productive in-
teractions with Frb-fused proteins can be restored by
mutation of Frb to accommodate the rapamycin analog
(a rapalog). We have quantitatively assessed the inter-
action between rapalogs functionalized at C16 andC20
and a panel of Frb mutants. Several drug-Frb mutant
combinations have different and nonoverlapping
specificities. TheseFrb-rapalogpartnerspermit the se-
lective control of different Frb fusion proteins without
crossreaction. The orthogonal control of multiple tar-
get proteins broadens the capabilities of chemical in-
ductionof dimerization to regulate biologic processes.
Introduction
Conditional regulation of gene activity greatly facilitates
the analysis of a gene’s function by isolating a loss or
gain of function to discrete periods of time. Several tech-
niques achieve conditional regulation, but temporal con-
trol of gene function at the protein level with small mole-
cules can greatly enhance the kinetics of experimental
regulation relative to strategies that rely on gene dele-
tion, transcription, or inhibitory RNAs.
We have developed an alternative approach to condi-
tional protein regulation that combines the specificity
possible with genetic techniques with the experimental
tractability of pharmaceutical intervention. This system
uses one class of small molecules to govern the activity
of a broad number of protein targets made sensitive to
the drug by fusion to a drug binding protein domain. It
is based on the biologic principle that proximity com-
monly regulates protein activity [1] and that chemical in-
duction of homo- or heterodimerization with small mole-
cules allows experimental control over the biochemical
activity of the target protein [2, 3]. The macrolides rapa-
mycin and FK506 act by inducing the heterodimerization
of cellular proteins. Each drug binds with high affinity to
the FKBP12 protein, creating a drug-protein complex
that subsequently binds and inactivates mTOR/FRAP
*Correspondence: crabtree@stanford.eduand calcineurin, respectively [4–6]. TheFKBP-rapamycin
binding (Frb) domain of mTOR has been defined [7] and
applied as an isolated 89 amino acid protein moiety
that can be fused to a protein of interest. Rapamycin
can then induce the approximation of Frb fusions to
FKBP12 or proteins fused with FKBP12 [1, 8–10]. Several
applications for this technology have been devised, in-
cluding the dimerization and activation of cell surface re-
ceptors that control cell growth, differentiation, and
death [2, 11, 12], subcellular localization of proteins
[13–17], and recruitment of transcriptional control units
to DNA binding proteins [8, 9, 18, 19]. More recently,
a technique has been devised in which latent protein tar-
gets fused to an unstable variant of Frb are stabilized by
the drug-directed recruitment of FKBP [10].
Rapamycin has several properties of an ideal dimer-
izer: it has a high affinity (KD < 1 nM) for Frb when bound
to FKBP12, and is highly specific for the Frb domain of
mTor. Rapamycin is an effective therapeutic immuno-
suppressant with a favorable pharmacokinetic and phar-
macodynamic profile in mammals; however, rapamycin
is a potent teratogen, discouraging its use for whole an-
imal protein dimerization studies [20, 21]. In fact, treat-
ment with rapamycin during mouse embryogenesis
gives the same embryonic lethal phenotype as the
mouse mTor mutant, flat-top [20] supporting the sin-
gle-target specificity of rapamycin. Modification of the
surface of rapamycin contacting Frb [22] can prevent
binding to mTor and mitigate the inhibitory effects of
rapamycin [10, 23]. Compensatory mutation of the Frb
domain to form a surface that accommodates the
‘‘bumped’’ rapamycin restores dimerizing interactions
only with the Frb mutant and not to the endogenous
mTor protein [23]. Reformation of the binding interaction
with the rapamycin analog or ‘‘rapalog’’ C20-methallylra-
pamycin (C20-Marap) was selected in a triple mutant Frb
termed Frb*.
In our recent studies, we have created Frb* fusions
with two mouse genes, GSK-3b and Pax6, by homolo-
gous recombination of Frb* coding sequences at the tar-
get genes ([10] and J.H. Bayle et al., submitted). In each
case, the Frb* fusion allele produces an unstable protein
with a loss-of-function phenotype in vivo, while treat-
ment with C20-Marap recruits FKBP and stabilizes the
latent GSK-3bFrb* or Frb*Pax6 protein to rescue protein
function. The rapid and reversible stabilization of Frb*-
tagged proteins has the potential to be a powerful con-
ditional allele system applicable to broad classes of
cytosolic proteins [10]. However the pharmacokinetics
of C20-Marap in vivo are poor.
To improve the technology for whole animal studies,
we wished to find rapalogs that also have specificity for
Frb* or other mutant Frb domains. Our first goal was to
improve the understanding of the efficient binding of
C20-Marap with Frb* relative to Frb at the primary struc-
tural level. We then screened new variant Frbs against
a group of rapalogs to find new drug-mutant combina-
tions that may have improved specificity or pharmacoki-
netics. As a result, we have built an array of Frb mutants
that have separate but overlapping specificities for
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of individual drug-mutant combinations permits the
development of dimerizer strategies that operate in an
independent or orthogonal manner in the same cell envi-
ronment. Each mutant was also assessed for its con-
tribution to the stability of the Frb domain to determine
if the altered protein conformations underlying drug
selectivity were also responsible for destabilization of
Frb. These results are reported by J.E. Gestwicki et al.
(submitted).
Results
The minimal Frb domain comprises amino acids 2025–
2114 of human mTor. Frb* is a triple mutant resulting in
the following amino acid substitutions in the 89 amino
acid four-helical Frb bundle: Lys2095 to Pro, Thr2098
to Leu, and Trp2101 to Phe. To understand the basis
for the specificity of C20-Marap for Frb* over wild-type
Frb, we have systematically analyzed the contribution
of each of the three substituted amino acids in Frb* by
making single and double mutant combinations from
the wild-type. The nomenclature for these mutants is
in a three letter code representing the amino acids posi-
tions that vary in Frb*, with the wild-type denoted as
KTW for Lys2095, Thr2098, and Trp2101. Frb* is denoted
as PLF in this system to represent the Pro, Leu, and Phe
substitutions at the corresponding positions.
Binding of rapamycin and C20-Marap was assessed
in a rapalog-dependent transcriptional switch in which
three copies of human FKBP12 were fused to the yeast
GAL4 DNA binding domain and the mutant (or wild-type)
Frb domain was fused to the potent transcriptional acti-
vation domain from the herpes simplex virus VP16 pro-
tein [8]. Coexpression of these recombinant constructs
in COS1 cells, together with a secreted bacterial alkaline
phosphatase (SeAP) reporter that contained Gal4-spe-
cific DNA binding elements, promoted SeAP expression
only in the presence of a rapalog capable of interacting
with FKBP and the Frb variant (Figure 1A). Transfected
cells were split into identical pools and dosed in tripli-
cate or quadruplicate with increased concentrations of
rapamycin or C20-Marap. With the wild-type Frb domain
(KTW) fused to VP16, increasing rapamycin or rapalog
concentrations stimulated SeAP activity with a sigmoid
dose dependence curve (Figure 1B). The half-maximal
activity (EC50) was 0.95 nM for rapamycin-FKBP binding
to KTW. This EC50 was close to the documented binding
constant for rapamycin-FKBP to the wild-type Frb [7],
demonstrating that the transcriptional switch provided
a good indicator of the strength of drug-FKBP binding
to the Frb domain. In the same assay with the wild-
type Frb (KTW), C20-Marap was able to stimulate re-
porter activity only at high drug concentrations, and
maximal reporter activity could not be attained (Figure
1B). In contrast, the triple mutant Frb(PLF) gave strong
reporter activity at low concentrations of C20-Marap
(Figure1C). This finding indicates that the lack of interac-
tion of C20-Marap with KTW was not due to impaired in-
teraction with FKBP (which was common to both as-
says), but rather a steric prevention of interaction
between the side chains of KTW with methallyl-bumped
drug. The steric bulk on C20-Marap was accommodated
by the amino acid substitutions on PLF, while binding ofrapamycin itself was not affected (Figure 1C). These re-
sults are in agreement with those previously reported
[10, 23].
The three amino acid substitutions in PLF confer
specificity for C20-Marap though it was unknown
whether all three mutations were required. To assess
the importance of each substituted amino acid to the ac-
commodation of the methallyl bump, we tested double
mutants that contained combinations of the substitu-
tions in PLF. Reversion to Trp2101 yielded a Frb double
mutant, termed PLW. This mutant reduced C20-Marap
binding (Figure 1D), while reversion at either of the other
positions (Thr2098 in PTF or Lys2095 in KLF) had less or
no effect on C20-Marap interaction (Figures 1E and 1F).
We found that rapamycin had a higher EC50 for the PTF
construct relative to PLF or KTW, while C20-Marap
bound PTF and PLF with equal efficiency. These results
indicate that the most important site of steric inhibition
was amino acid 2101, and a principal source of drug
specificity was likely the plasticity afforded the phenyl
of Phe at this position to accommodate the methallyl
on C20-Marap. This proposal was supported by the rel-
atively efficient interaction of C20-Marap with the single
mutant KTF in which only Trp2101 was modified from
wild-type (Figure 2D).
The C20-Marap-PLF combination is ideal for in vivo
studies, as C20-Marap does not bind effectively to the
wild-type Frb domain of mTor; however, C20-Marap is
more unstable in animal serum than rapamycin and
other rapalogs. Therefore, we tested other rapalogs de-
rivatized at the interacting surface with Frb for specific-
ity to Frb mutants at Trp2101 and Thr2098. Interestingly,
we observed a specificity for one derivative, C16-(S)-bu-
tylsulfonamidorapamycin (C16-BSrap) opposite to that
of C20-Marap (Figure 2). C16-BSrap bound efficiently
to the wild-type Frb (KTW), but not to PLF or the single
mutant KTF, indicating that the Trp to Phe variation
was the source of the different specificity between these
two rapalogs. The parent drug, rapamycin, was capable
of binding to each mutant.
This observation led us to develop and screen a group
of rapalogs substituted at C16 or C20, positions directly
opposing helix 4 of Frb, for specific interactions with Frb
mutants. Some rapalogs added steric bulk at these po-
sitions with a planar aromatic group or with groups that
have a wider conformational space, while other modifi-
cations were predicted to add flexibility to rapamycin.
The chemicals were synthesized for this study or pro-
cured from Ariad Pharmaceuticals (Cambridge, MA) or
Novartis AG (Basel, Switzerland). One interesting rapa-
log was synthesized by acid-mediated production of
a carbocation at C16 that was quenched with 3-methyl-
indole to produce C16-(S)-3-methylindolerapamycin
(C16-iRap). This rapalog had an Frb specificity profile
that differed from both C16-BSrap and C20-Marap. Sub-
stitution of Phe for Trp2101 prevented binding of C16-
iRap only in the context of Thr at position 2098 (Figure 3).
Substitution to Leu 2098 in the KLF double mutant re-
versed the steric block in KTF and permitted binding
of C16-iRap with an EC50 similar to KLW. Similarly,
Thr2098 was permissible only in the context of Trp at
2101.
The number of mutants screened against the rapalogs
described above was expanded to include combinations
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101Figure 1. C20-Methallylrapamycin Binds Specifically to a Mutant Frb Domain Containing Phe at Amino Acid 2101
(A) Schematic diagram of rapamycin- or rapalog-directed transcription switch. FKBP12 is fused to the yeast Gal4 DNA binding domain, which
is tethered to reporter plasmid DNA containing Gal4-specific DNA recognition elements. In the absence of drug, transcription of secreted bac-
terial alkaline phosphatase is low. Inclusion of rapalog recruits Frb fused to a VP16 transcriptional activation domain to the promoter and SeAP
transcription is stimulated.
(B–F) SeAP activity in transfected COS cells containing the transcriptional switch and stimulated with increasing concentrations of rapamycin
(squares) or C20-methallylrapamycin (C20-Marap; triangles). Frb-VP16 constructs are denoted above the graphs in single-letter amino acid
code indicating positions 2095, 2098, and 2101 with (B) utilizing Lys2095, Thr2098, and Trp2101 (the wild-type) and (C) Pro2095, Leu2098,
and Phe 2101 (aka Frb*). Residues mutated from the wild-type are red and italicized.
Error bars represent 6 1 SD.with alanine, proline, or threonine substituted for
Lys2095, and additional substitutions at Thr2098 were
also screened. The results of this screen standardized
between experiments with the EC50 of rapamycin against
Frb KTW are presented in Table 1. Several of these mu-tants, notably those with Phe at amino acid 2101 and
Thr at 2098, had a reduced affinity for rapamycin (com-
pare KTF with KTW or KLF; similarly, compare PLF with
PTF) and, in some cases, appeared to bind effectively
to other drugs (compare C20-Marap and rapamycin on
Chemistry & Biology
102Figure 2. Discrete Frb Binding Specificities Are Conferred by Modification of Rapamycin
(A) Chemical structures of rapamycin, C20-Marap and C16-(S)-butylsulfonamidorapamycin (BS-Rap).
(B–D) SeAP reporter activity in the rapalog-dependent transcriptional switch plotted at increasing concentrations of rapamycin (squares), C20-
Marap (triangles), or C16-BSrap (circles) with the Frb variant PLF (B), KTW (C) or KTF (D).
Error bars represent 6 1 SD.PTF [Figure 1E]). In general, variation at Lys2095 had little
effect on drug binding. C16-BSrap and C16-AiRap
bound poorly to all mutants with Phe at 2101 despite
the context of mutations at the other positions. C16-
(S)-7-methylindolerapamycin (AP21967, also denotedC16-AiRap in this study), another indole derivative at
C16, but with the indole inverted relative to the linkage
of C16-iRap, does not interact efficiently with wild-type
Frb (KTW), and has an intermediate binding for mutants
with Leu 2095 only if Trp2101 remains wild-type (theFigure 3. Binding Specificity of Bumped Ra-
palogs Depends on Variation at Frb Amino
Acids 2098 and 2101
(A) Chemical structures of C16-(S)-3-methylin-
dolerapamycin (C16-iRap) and C16-(S)-7-
methylindolerapamycin (AP21967/C16-AiRap).
(B) SeAP reporter assays were performed
with Frb variants KTW, KLW, KTF, and KLF
with increasing concentrations of C20-Marap
(red), C16-BSrap (orange), C16-iRap (green),
and AP21967 (black). Results are plotted as
the inverse of the EC50 for the drug-Frb variant
combination in megamolar scale. Low (or
zero) values thereby indicate a high EC50. *In-
teraction too weak to be calculated.
Error bars represent 6 1 SD.
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had a similar EC50 as AP21967 if Thr2098 was changed
to Leu in the context of Trp at 2101 (compare KTW with
KLW), but the binding was dramatically improved if
Trp2101 was changed to Phe. While little specific effect
on drug binding was observed if Lys2095 was mutated,
variation at this position could influence the stability of
the Frb domain in combination with substitutions at
Thr2098 (J.E. Gestwicki et al., submitted).
Table 1. EC50 of Rapamycin and Four Rapalogs for Frb Variants












KTW 0.45 —a 2.7 2.3 —a
PLF 0.80 4.5 —a 6.1 —a
KLW 3.2 52 16 1.2 37
PLW 5.0 30 26 13 26
TLW 2.1 34 7.4 4.6 19
ALW 1.7 34 7.5 4.3 19
PTF 3.3 4.5 —a —a ND
ATF 2.7 15 —a —a ND
TTF 3.0 13 —a —a ND
KLF 0.93 4.5 —a 6.1 —a
PLF 0.8 4.5 —a 6.4 —a
TLF 1.6 8.5 —a 4.3 —a
ALF 1.6 1.0 —a 12 —a
KTF 1.8 9.3 —a —a —a
KHF 1.5 6.5 —a 14 ND
KFF 2.2 15 —a —a ND
KLF 0.93 4.5 —a 12 —a
Values are measured in the rapalog-dependent transcriptional
switch and restandardized for transfection efficiency between ex-
periments according to the EC50 of rapamycin against KTW or
PLF. ND, not determined.
a A half-maximal concentration greater than 150 nM that cannot be
determined accurately.Orthogonal Rapalog-Dependent Systems
Drug-dependent protein dimerization has many applica-
tions for the control of protein function in vivo, including
the inducible stabilization of targets fused to an unstable
Frb mutant, the ligand-directed activation of signal trans-
duction, the selective control of transcription, and the
subcellular localization of target proteins. The specificity
of rapalogs with different derivative groups for interac-
tion with individual Frb mutants provided a foundation
to develop multiple rapalog-dependent systems that
share components but can be regulated independently.
To demonstrate the possibilities and efficacy of or-
thogonal regulation, we attempted to regulate the sub-
cellular compartmentalization of a single target protein
differentially using specific rapalogs. GSK-3b is a kinase
and a key regulator of multiple intracellular signaling
pathways that is normally localized both in the nucleus
and cytoplasm. GSK-3b was fused with FKBP12 and
coexpressed with two different Frb mutants tagged
with orthogonal subcellular targeting signals. Frb(TLW)
was fused to an 11 amino acid nuclear export sequence
derived from the Rev protein of human immunodefi-
ciency virus to produce TLW-exp, and KTF was fused
to two copies of the 7 amino acid nuclear localization se-
quence from SV40 Large T antigen.
In the absence of drug, GSK-3b was observed both in
the cytoplasm and nucleus (Figure 4A). C20-Marap binds
efficiently to KTF, but inefficiently to the TLW mutant.
Addition of 10 nM C20-Marap resulted in localization of
GSK-3b to the nucleus due to dimerization of the GSK-
3b-FKBP target, with KTF-Imp in preference to TLW-
Exp (Figure 4C). Stimulation with C16-BSRap had the
opposite targeting effect, and GSK-3b-FKBP was rapidly
localized to the cytoplasm by selective recruitment of the
KTW-Exp (Figure 4B). Interestingly, the majority of cells
incubated with rapamycin also localized GSK-3b-FKBP
to the cytoplasm (Figure 4D).Figure 4. Orthogonal Control of GSK-3b Subcellular Localization with Specific Rapalogs
FKBP-GSK-3b-GFP is coexpressed with Frb(TLW)-NES and Frb(KTF)-NLS. GFP is visualized in transiently transfected COS1 cells without
stimulation where GSK-3b is localized to both cell compartments (A) or with 1 hr stimulation with (B) 10 nM C16-BSrap, (C) 10 nM C20-Marap,
or (D) 10 nM rapamycin. Illustrations beneath each figure depict the drug-selective recruitment of either TLW-exp or KTF-imp to FKBP-GSK-3b
to direct nuclear import or export.
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Acids 2098 and 2101 in Frb that Underlie
the Specificity of Given Rapalogs
(A) Different Frb varients are listed in illustated
form with ‘‘X’’ representing amino acid 2095.
The relative strength of interaction with the ra-
palogs listed on the right is indicated by the
thickness of the line.
(B) Ribbon diagram of the crystal structure of
the Frb-rapamycin complex [22] with the
amino acids altered in this study space-filled
as indicated along with rapamycin (gray).Discussion
Our identification of the amino acids critical to the spec-
ificity of C20-Marap for Frb*/PLF has uncovered new
specific drug-protein interactions that will broaden the
capabilities of induced dimerization to regulate biologic
function. Specifically, we found that amino acids 2098
and 2101 underlie the binding specificity of rapalogs de-
rivitized at C16 and C20. Substitution with phenylalanine
at 2101 permits strong binding of C20-Marap, while this
substitution prevents binding of the C16 derivatives. If
threonine 2098 is replaced with leucine, binding of
C16-AiRap/AP21967 and C20-Marap is enhanced and
C16-iRap binding interactions are reformed in the con-
text of Trp at 2101. Thus, each of the rapalogs has
a unique, partially overlapping, and occasionally oppo-
site binding specificity for Frb mutant combinations at
2098 and 2101: C20-Marap with ‘‘TF’’ and ‘‘LF,’’ C16-
BSrap with ‘‘TW’’ and ‘‘LW,’’ C16-iRap with ‘‘TW,’’
‘‘LW’’ and ‘‘LF,’’ and C16-AiRap/AP21967 with ‘‘LW’’ ex-
clusively (Figure 5A).
In the crystal structure of FKBP-rap in complex with
the Frb domain, Trp2101 is partially buried between he-
lix 4 and helix 1 of the Frb four-helix bundle. The planar
aromatic surface of the indole side chain opposes the
coordinated triene between C17 and C22 of rapamycin
[22]. It appears that the steric bulk of the methallyl group
of C20-Marap directed into the indole ring can be ac-
commodated by substitution of the indole for the phenyl
ring of Phe. The methallyl addition at C20 also breaks the
conjugation of the triene and may permit greater tor-
sional flexibility in the drug as well as adding bulk. It is
not known how the altered rapamycin conformation
may contribute to the drug’s specificity; however, the in-
creased flexibility of the rapamycin backbone may con-
tribute to the drug’s instability in animal serum.
The different binding specificities of C16-iRap and
C16-AiRap/AP21967 are particularly interesting, as each
rapalog has a planar indole substitution in the same
stereoconformation but with a different linkage to C16.
Unlike other rapalogs with bulky additions at C16, C16-
iRap will bind to Frb mutants with a Trp2101-to-Phe sub-
stitution, but only if Leu is at position 2098. The indole
ring in either orientation points into the interface with he-
lix 4 of the Frb domain in close proximity to amino acids
2098 and 2101. There is relatively little bulk added by
substituting Phe for Trp, and it appears confounding
that substitution of Leu, with a bulky side chain, for Thr
at 2098 should accommodate C16 bumps on rapamycin.
It is possible that these substitutions accommodate the
bumps by altering the secondary structure of helix fourslightly. Supporting this notion, the DDG of the Frb do-
main is greatest when Leu is substituted for Thr at 2098
(J.E. Gestwicki et al., submitted).
These studies are part of our development of rapalog-
directed dimerization as a method for conditional pro-
tein regulation in vivo. We chose to make discrete site-
directed mutations that were primarily reversions of
the Frb*(PLF) triple mutant to refine our understanding
of the basis for the specificity of C20-Marap for PLF
over the wild-type (KTF) and determine if this specificity
could be separated from the structural instability of PLF.
A further screen of randomly generated mutations, such
as a recursive analysis in mammalian cells [23] or yeast
[24], will likely yield mutant Frbs with enhanced affinity
for the individual rapalogs described here and therefore
enhanced specificity for orthogonal regulation of Frb-
tagged proteins.
The Frb mutants described in this article have been
examined for their thermal stability relative to wild-type
(KTW) and their ability to be stabilized in vivo in the pres-
ence of rapamycin (J.E. Gestwicki et al., submitted). Im-
portantly, the combinations of amino acid substitutions
that destabilize Frb, and therefore lead to the greatest
degree of induced stabilization, can be separated from
those that determine drug specificity. This has important
consequences for the utility of rapalogs in conditional
systems that act in a ‘‘drug-on’’ fashion, such as the
drug induction of a latent, destabilized Frb fusion, ver-
sus a ‘‘drug-off’’ system, such as the drug-targeted mis-
localization of an active nuclear protein to the cyto-
plasm. It should be noted that saturation of a target
protein with the drug-targeting element is likely to be re-
quired to give productive mislocalization.
The overlapping (and in some cases unique) specific-
ity of individual rapalogs for different Frb mutants
broadens the possibilities for the conditional regulation
of protein function with rapalog-directed dimerization
(Figure 6). Multiple target proteins can be coexpressed
as fusions with different Frb variants to permit their co-
ordinated, orthogonal regulation. As an example, two
transcription factors can be expressed, one fused with
KTW and the other with KTF with the exporter FKBP-
NES also expressed (Figure 6A). In the presence of
C16-BSrap, only the KTW-fused target is exported
from the cell nucleus, while C20-Marap will induce the
export of the KTF-fused target.
Like most chemically regulated biologic systems, the
rapalog-induced effect is reversed after treatment is dis-
continued or replaced with a competitor. This property
can be utilized selectively by treatment with a drug that
binds to both Frb mutants to produce a response, and
Orthogonal Protein Regulation with Rapamycin Analogs
105Figure 6. Schematics of Applications for Orthogonal Control of Protein Function with Rapalogs
(A) Selective recruitment of FKBP-NES ‘‘exporter’’ protein to Frb-tagged fusions with specific rapalogs and Frb variants. C20-Marap selectively
exports an Frb(KTF)-protein target (left), while BS-rap selectively exports a Frb(KTW)-protein fusion (right).
(B) Selective stabilization of protein targets fused to unstable Frb variants. Fusion of protein targets to Frb (KLF) or Frb (PLW) leads to their
degradation. Both Frb variants can interact and be stabilized by C16-iRap by recruitment of FKBP. Replacement of C16-iRap with C20-Marap
(upper) or C16-BSrap permits the continued stabilization of only the target capable of maintaining specific interaction with the Frb variant and
the rapalog.later switching to a drug that only interacts with only one
of the Frb fusions. As an example (Figure 6B), one protein
is fused to the partially unstable Frb PLW and the other
with KLF. In the presence of C16-iRap, both fusions are
stabilized and active because this drug recruits FKBP
to each mutant. When C16-iRap is washed out and re-
placed with C16-BSrap, FKBP-BSrap is no longer re-
cruited to the KLF fusion to degrade while the PLW fusion
remains stabilized. Similarly, switching from C16-iRap to
C20-Marap selectively retains stabilized KLF fusions.
An alternative use for orthogonal rapalogs in regula-
tion is the differential regulation of a single target protein
fused to FKBP by the specific recruitment of one of mul-
tiple Frb-tagged regulatory domains. In an example from
this study, the kinase GSK-3b, which is localized both in
the cytoplasm and the nucleus, is fused with FKBP and
selectively recruited to or exported from the nucleus
with rapalog-specific Frb mutants fused to a nuclear lo-
calization sequence or nuclear export sequence, respec-
tively. Such systems can be useful to parse nuclear func-
tions from cytoplasmic functions for proteins that have
roles in multiple signaling pathways. Other examples in
which a ‘‘one target, multiple effect’’ strategy can be em-
ployed include transcriptional regulation, in which the
DNA binding domain of a transcription factor of interest
is stripped of its domains that influence transcriptionand fused with FKBP. Selective recruitment of an activa-
tion domain or a repression domain (or both, in se-
quence) with specific rapalogs gives the experimentalist
greater control of the timing of subsequent biochemical
effects of stimulated or repressed transcription [18, 19].
Similarly, recruitment of kinases and phosphatases to
nodes of signaling activity can facilitate subsequent pro-
teomic analysis of the effect of this recruitment. We ex-
pect that the available technologies based on chemical
induction of dimerization can be significantly broadened
by the use of combinations of Frb fusions and rapalogs,
both for the characterization of biologic responses and
biochemical effects.
Significance
Earlier studies [10, 23] found that drugs bumped at the
C20 position of rapamycin could alleviate the inhibi-
tory effects of rapamycin and permit chemical induc-
tion of dimerization in vivo. The triple mutant selected
to accommodate the bump on rapamycin (PLF) desta-
bilizes the Frb domain and transfers this instability to
proteins fused to Frb [10], an effect reversed by rapa-
log recruitment of FKBP. The drug-specific and de-
stabilizing properties of PLF could have been the re-
sult of a structural ‘‘loosening’’ of Frb that permits
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protein surface. The results of this study do not favor
such amodel, as other rapalogs bumped along the Frb
binding surface do not bind to PLF, but instead inter-
act with other Frb mutants. This finding supports a
lock-and-key model for rapalog-Frb mutant binding
with destabilization a separate consequence. In fact,
some mutants that interact with C20-Marap are not de-
stabilizing to Frb (J.E. Gestwicki et al., submitted). The
specificity of mutant Frb domains for different rapa-
logs permits the orthogonal regulation of multiple
Frb-fused target proteins. Several schemes are pre-
sented to take advantage of this improvement of di-
merizer technology. Perhaps the most important ad-
vantage of this advancement to biologists is the
coordinated experimental regulation of multiple pro-
teins in a biological pathway. Determining order in a
pathway such as a signal transduction cascade is per-
formed genetically through tests of epistasis. In this
test, mutants with distinct phenotypes are crossed,
and the mutant whose phenotype is evident is deter-
mined to be downstream in a pathway. These powerful
experiments require that mutants, both loss- or gain-
of-function or at least with distinguishable pheno-
types, exist—a tall order in mammalian systems.
Chemical regulation of one Frb-tagged protein in com-
bination or discord with another will facilitate the as-
signment of order in biological pathways through a
sort of chemical epistasis.
Experimental Procedures
Chemistry
NMR spectra were recorded on a Varian UI-500 (500 MHz for 1H, 125
MHz for 13C) and AM-400 (400 MHz for 1H, 100 MHz for 13C) spec-
trometers. Chemical shifts are reported in ppm from tetramethylsi-
lane using the solvent resonance as an internal standard (dimethyl-
sulfoxide, 2.49 ppm in 1H NMR and 39.5 ppm in 13C NMR). Infrared
spectra were recorded on a Perkin Elmer Spectrum BX FTIR System.
Mass spectral data were acquired at the Stanford University Vincent
Coates Foundation Mass Spectrometry Laboratory. Dichlorome-
thane was distilled over calcium hydride prior to use. All other mate-
rials were used without purification. The syntheses of C16-alkoxy ra-
pamycin analogs followed the method of Clardy and Holt [25].
C16-(S)-3-methylindolerapamycin
To a flame-dried and argon-cooled 25 ml round-bottom flask was
added rapamycin (50.3 mg, 55.0 mmol), 3-methylindole (14.4 mg,
110.0 mmol), and CH2Cl2 (5.0 ml). This solution was cooled to
240ºC and trifluoroacetic acid (17.0 ml, 220.0 mmol) was added. After
5 hr at240ºC, 8 ml ethyl acetate and 8 ml brine were added. The so-
lution was warmed to room temperature, the layers separated, and
the organic layer dried with sodium sulfate. After concentration un-
der reduced pressure, the crude material was chromatographed us-
ing a mobile phase gradient of 1:1 hexanes:ethyl actetate to 2:3 hex-
anes:ethyl acetate to yield 55.1 mg (99%) of the desired product.
Purity was demonstrated by HPLC using a methanol:water:acetoni-
trile (36:13:1) mobile phase, a Waters XTerra phenyl 5 mm column at
50ºC, and monitoring at 278 nm. The C16-(S) stereochemistry was
assigned by comparison of the C22 chemical shift in the 1H NMR
spectra of the product with rapamycin and C16-(R)-trimethoxy-
phenyl rapamycin [25, 26]. Only the trans-conformer is described
in the 1H NMR characterization. IR (film) 3418 s, 2931 min, 1717 s,
1652 s, 1456 min, 1386 w, 990 w, 737m. 1H NMR (400 MHz, DMSO-
d6, 25ºC) 10.03 (s, 1H), 7.36 (d, 1H, J = 8 Hz), 7.25 (d, 1H, J = 8 Hz),
6.98 (t, 1H, J = 7 Hz), 6.91 (t, 1H, J = 7 Hz), 6.44–6.08 (m, 5H), 5.43
(dd, 1H, J = 10, 15 Hz), 5.25 (d, 1H, J = 4 Hz), 5.20 (d, 1H, J = 10
Hz), 5.05 (m, 1H), 4.91 (d, 1H, J = 6 Hz), 4.59 (d, 1H, J = 4 Hz), 4.09
(m, 1H), 3.98 (d, 1H, J = 4 Hz), 3.66 (m, 1H), 3.32–3.29 (m, 7H),
3.18–3.16 (m, 3H), 2.92–2.78 (m, 2H), 2.46–2.38 (m, 2H), 2.26–2.06(m, 3H), 2.14 (s, 3H), 2.04–1.50 (m, 13H), 1.46–1.06 (m, 12H), 1.04–
0.80 (m, 15H), 0.74–0.56 (m, 4H). 13C NMR (125 MHz, DMSO-d6,
25ºC) d210.4, 208.1, 199.0, 169.2, 167.1, 140.3, 138.1, 137.2, 135.4,
135.2, 130.8, 129.0, 128.4, 125.1, 122. 7, 120.1, 117.9, 117.5, 110.5,
106.6, 98.9, 85.6, 83.8, 75.6, 73.3, 73.3, 66.9, 57.0, 56.8, 51.1, 44.8,
43.6, 38.5, 38.1, 35.3, 34.9, 33.5, 32.9, 32.6, 31.5, 31.4, 29.0, 26.6,
26.1, 24.5, 21.8, 20.4, 17.4, 16.0, 15.5, 14.7, 13.7, 13.2, 8.6. HRMS cal-
culated for C59H85N2O12 (M+H): 1013.6103 amu, found (ESI)
1013.6096 amu.
Synthesis of C20-methallylrapamycin is described in Stankunas
et al. [10]. C16-(S)Butylsulfonamidorapamycin (AP23050) and C16-
(S)-7-methylindolerapamycin (AP21967) were generously provided
by Drs. Tim Clackson and Victor Rivera at Ariad Pharmaceuticals.
Mutagenesis
All Frb mutants were prepared by the quikchange mutagenesis
method (Stratagene, San Diego, CA) using the protocols provided
by the manufacturer. Briefly, PCR reactions containing the parent
plasmid pBJ5-Frb-VP16-HA or pBJ5-Frb*-VP16-HA and overlap-
ping oligonucleotides containing the relevant base changes were
performed with Pfu polymerase (Stratagene). PCR reactions were
digested with the methylation-sensitive restriction endonuclease
Dpn1 to eliminate the parent plasmid and the reaction was trans-
formed in XL10-Gold Ultracompetent E. coli (Stratagene). All mu-
tants were confirmed by sequencing.
SeAP Assay
Drug efficacy was determined in a three-plasmid transcriptional
switch reporter assay. w106 COS1 cells were coelectroporated
with 2 mg of the DNA binding construct pBJ5-Gal4-FKBP(3), 2 mg
pBJ5-Frb-VP16 (or the relevant mutant Frb) and 2 mg of the Gal4-
SeAP reporter. Electroporation details are available upon request.
Cells were immediately aliquoted to 96-well plates with flat bottoms.
After 24 hr incubation media was supplemented with rapalog in trip-
licate and in serial 2-fold dilutions. Following 24 hr further incuba-
tion, cells with media were wrapped carefully in plastic wrap and
heated to 65ºC for two hours to inactivate endogenous phospha-
tases. 50 ml of media was transferred to a black 96-well plate (Costar
3915) and supplemented with 50 ml 1mM Methylumbelliferrylphos-
phate (Sigma, St. Louis, MO) in 1 M Diethanolamine (pH 10.0 with
carbonate). After 16 hr incubation at 37ºC, SeAP activity was mea-
sured by fluorescence with a Spectamax M2 fluorometer (Molecular
Devices, Sunnyvale, CA) with transmission set at 355 nM and emis-
sion at 460 nM. Data were analyzed with Softmax Pro (Molecular De-
vices), Microsoft Excel, and Prism 3 (GraphPad Software).
Transfections and Staining
COS1 cells were electroporated with 1 mg pS-FKBP-GSK-3b-GFP, 1
mg of the ‘‘exporter’’ pBJ5-Frb(TLW)-Exp-HA containing a nuclear
export sequence derived from the rev protein of human immunode-
ficiency virus and 3 mg of the ‘‘importer’’ pBJ5-Frb(KTF)-Imp with
a nuclear localization sequence from SV40 Large T antigen. Cells
were plated on autoclaved coverslips and incubated for 36 hr, fol-
lowed by 1 hr of rapalog treatment (10 nM). Cells were fixed for 10
min in 4% paraformaldeyde/PBS at 4ºC and mounted for micros-
copy with DAPI to visualize the nucleus. Microscopy was performed
with a Leica confocal microscope and Leica software.
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